Martha L. Doemland, Ph.D.

Dr. Doemland has over 30 years of experience in the design, implementation, management, analysis, and interpretation of epidemiologic studies related to both chronic and infectious diseases. Prior to joining Exponent, Dr. Doemland was with Sanofi Pasteur, the vaccine division of Sanofi-Aventis, from 2003 to 2010, where she served as Director of Epidemiology, with responsibility for the epidemiologic research strategy for vaccines under development and in early clinical trials. The research strategy, developed through a comprehensive disease understanding, focused on assessing the current state of knowledge, including an assessment of potential clinical trial endpoints, potential pharmocoepidemiologic issues, and disease risk factors, and establishing profiles for the “at risk” population; as well as proposing and conducting studies to measure and monitor the global incidence/prevalence of the disease or infection. She designed studies to measure the incidence and prevalence of healthcare-acquired infections and sexually transmitted diseases using claims and administrative databases (e.g., Premier/i3/United Health). Dr. Doemland was also involved in monitoring the epidemiology of vaccine-preventable diseases to assess the impact of vaccination on the incidence and prevalence of disease, and to discern changes in circulating strains of the pathogen. While at Sanofi Pasteur, she developed a comprehensive understanding of the vaccine development process through the entire life cycle, and in particular the important role of observational studies in vaccine development in both the pre- and post-licensure phases.

Dr. Doemland has wide-ranging experience managing and analyzing large data sets, ranging from occupational cohorts to large patient populations (patients undergoing coronary angiography or coronary bypass surgery at a large teaching hospital), including analyses of cohort mortality to survival, and calculating measures of incidence and prevalence using national databases (National Inpatient Survey, CDC Wonder).

Dr. Doemland has comprehensive knowledge and experience in assessing health effects from occupational and environmental exposures in both adults and children. Most notably, she was the co-principal investigator and project manager of a large occupational study of workers exposed to polychlorinated biphenyls in which follow-up spanned more than 60 years. As part of this epidemiologic research, she gained extensive experience conducting vital status determination using the National Death Index and other sources.

Greenberg DP, Doemland M, Bettinger JA, Scheifele DW, Halperin SA; IMPACT Investigators, Waters V, Kandola K. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: Implications for disease prevention in the United States. Pediatric Infectious Disease Journal 2009 Jun; 28(6):521–528.

Kimbrough RD, Doemland ML, Mandel JS. A mortality update of male and female capacitor workers exposed to polychlorinated biphenyls. Journal of Occupational and Environmental Medicine 2003; 45:3.

Kimbrough RD, Doemland ML, Krouskas CA. Analysis of research studying the effects of polychlorinated biphenyls and related chemicals on the neurobehavioral development in children. Veterinary & Human Toxicology 2001; 43(4)220–228.

Kimbrough RD, Doemland ML, LeVois ML. Mortality in male and female capacitor workers exposed to PCBs. Journal of Occupational and Environmental Medicine 1999; 41(3):161–171.

Freudenheim JL, Russell M, Trevisan M, Doemland ML. Calcium intake and blood pressure in blacks and whites. Ethnicity and Disease 1991; 1(2).

Rosenthal TC, Perrapato TH, Doemland ML, Fridorich JE, et al. Endometrial sampling: Analysis of 310 procedures performed by family physicians. Journal of Family Practice 1989; 29(3):249–256.

Book Chapters

Kimbrough RD, Doemland ML, LeVois ML. Mortality in male and female capacitor workers exposed to PCBs. In: Standard Handbook of Environmental Science, Health, and Technology. Lehr J (ed), McGraw-Hill, 2000.

Abstracts, Posters, and Oral Presentation

Doemland ML, Trevisan M, Krogh V, Winkelstein W. Sleep patterns and blood pressure results from the Buffalo Blood Pressure Study. Abstracts, American Journal of Hypertension 1989; 2(5): Part 2.

Htar MTT, Doemland M, Muros-Le Rouzic E. Global incidence and case fatality rates due to different N. meningitides serogroups. Poster, 17th International Pathogenic Neisseria Conference, Cairns, Australia, September 2007.

Greenberg DP, Doemland ML, Lavigne P, Galanis E, Kandola K, Bettinger J, Halperin SA, Scheifele DA, on behalf of the Immunization Monitoring Program. Active (IMPACT) Impact of Pentacel™ (DTaP-IPV//PRP-T) on the epidemiology of invasive Hib disease and pertussis in Canada. Poster, 5th Annual Pediatric Infectious Disease Society, Napa, CA, October 9–11, 2005.

Muros-Le Rouzic E, Doemland M, Teyssou R. Geographical differences in invasive meningococcal disease rates and serogroup distribution. Oral Presentation, Canadian Public Health Association Meeting, Ottawa, Ontario, September 2005.

Muros-Le Rouzic E, Doemland M, Teyssou R. Geographical differences in invasive meningococcal disease rates and serogroup distribution. Poster, 8th European Monitor Group for Meningococci Meeting Dublin, Ireland, September 7–9, 2005.